Free Trial

Wellington Management Group LLP Buys 854,346 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Replimune Group logo with Medical background

Wellington Management Group LLP increased its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 352.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,096,744 shares of the company's stock after purchasing an additional 854,346 shares during the quarter. Wellington Management Group LLP owned approximately 1.42% of Replimune Group worth $13,282,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its position in Replimune Group by 11.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after purchasing an additional 1,083,633 shares during the period. Redmile Group LLC increased its position in shares of Replimune Group by 2.6% during the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock worth $59,406,000 after buying an additional 124,344 shares during the period. Vanguard Group Inc. increased its position in shares of Replimune Group by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 3,595,848 shares of the company's stock worth $43,546,000 after buying an additional 129,601 shares during the period. Tang Capital Management LLC raised its stake in Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock worth $32,697,000 after buying an additional 1,500,000 shares during the last quarter. Finally, RTW Investments LP lifted its holdings in Replimune Group by 82.1% in the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after buying an additional 931,223 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. HC Wainwright increased their price target on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Piper Sandler upped their target price on Replimune Group from $14.00 to $22.00 and gave the company an "overweight" rating in a research report on Monday. Finally, JPMorgan Chase & Co. lifted their target price on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $19.75.

Check Out Our Latest Report on REPL

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,952 shares of the company's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $64,093.12. Following the sale, the insider now owns 146,933 shares in the company, valued at $1,184,279.98. This represents a 5.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Sushil Patel sold 25,105 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $202,346.30. Following the completion of the transaction, the chief executive officer now directly owns 343,576 shares in the company, valued at approximately $2,769,222.56. The trade was a 6.81% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 74,907 shares of company stock valued at $603,655. 8.80% of the stock is owned by company insiders.

Replimune Group Stock Up 0.6%

Shares of REPL stock traded up $0.06 on Wednesday, reaching $9.69. 1,033,156 shares of the company were exchanged, compared to its average volume of 946,846. Replimune Group, Inc. has a one year low of $4.93 and a one year high of $17.00. The company has a market cap of $746.97 million, a price-to-earnings ratio of -3.16 and a beta of 0.68. The company has a 50-day moving average of $8.35 and a 200-day moving average of $11.06. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter in the previous year, the business earned ($0.25) earnings per share. Analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

About Replimune Group

(Free Report)

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Recommended Stories

Institutional Ownership by Quarter for Replimune Group (NASDAQ:REPL)

Should You Invest $1,000 in Replimune Group Right Now?

Before you consider Replimune Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.

While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines